saplin

Bajaj Finserv Healthcare Fund

Bajaj Finserv Healthcare Fund (Direct, Growth): saplin Score 7.8/10 (Neutral) among 14 Sectoral/Thematic funds. 1Y return 26.1%, expense ratio 0.90%. Returns that beat most peers, with nothing standing out as a weakness. NAV ₹12.53 on 11 Nov 2026.

Loading the full analysis…

Questions about Bajaj Finserv Healthcare Fund

What is the expense ratio of Bajaj Finserv Healthcare Fund?

The Direct plan's total expense ratio is 0.90% a year, against a median of 1.04% for sectoral/thematic funds. The Regular plan costs more because it pays a distributor's commission.

Who manages Bajaj Finserv Healthcare Fund?

Bharat Hegde (since 28 Sept 2026); Sorbh Gupta (since 28 Sept 2026); Siddharth Chaudhary (since 27 Dec 2024).

What are the top holdings of Bajaj Finserv Healthcare Fund?

Divi's Laboratories 10.55%, Sun Pharmaceutical Industries 8.21%, Rubicon Research 6.81%, Piramal Pharma 6.72%, Aurobindo Pharma 6.18% of the portfolio, as of 31 Aug 2026.

What returns has Bajaj Finserv Healthcare Fund given?

1 year: 26.1% (category median 21.9%). Past returns do not predict future ones.

How big is Bajaj Finserv Healthcare Fund?

About ₹389 cr (AMFI's average for the latest quarter).

How does Bajaj Finserv Healthcare Fund score?

7.8 out of 10 (Neutral) on the saplin Score, which rates a fund against its own category on returns, risk, consistency, cost and its manager. See the methodology for how it is worked out.